Claims for Patent: 7,928,122

Summary for Patent: 7,928,122

Title:	Modulators of cellular adhesion
Abstract:	The present invention provides compounds having formula (I); and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
Inventor(s):	Wang Shen, Kenneth Barr, Johan D. Oslob, Min Zhong
Assignee:	Bausch and Lomb Ireland Ltd
Application Number:	US12/537,147
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,928,122
Patent Claims:	1. A compound of the following structure: or pharmaceutically acceptable salts thereof; wherein —C(═O)NHC(R1)(R2)R3 is a moiety having the following structure: R3A is hydrogen; RS is hydrogen; Ar2 is: s is an integer of 1; each occurrence of RP1 is independently hydrogen, halogen, or -GRG1, wherein G is —SO2—, or —SO2NRG2—; and RG1 and RG2 are independently hydrogen, an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety; RE is hydrogen; R4A and R4B are each Cl; L is C═O; and AR1 is 2. The compound of claim 1 wherein RP1 is selected from the group consisting of halogen and -GRG1, wherein G is —SO2— and RG1 is methyl. 3. The compound of claim 2 wherein AR1 is and RP1 is selected from the group consisting of F and SO2CH3. 4. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or diluent, and optionally further comprising an additional therapeutic agent. 5. A method of treating an immune or inflammatory response or disorder in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1, wherein the response or disorder is selected from psoriasis, inflammatory bowel disease, adult respiratory distress syndrome, dermatitis, meningitis, uveitis, eczema, asthma, poison ivy, poison oak, Sjogren's syndrome, pulmonary fibrosis, and rheumatoid arthritis. 6. The method of claim 5, further comprising concurrent, prior, or subsequent administration of an additional therapeutic agent. 7. A compound of the following structure: or pharmaceutically acceptable salts thereof; wherein —C(═O)NHC(R1)(R2)R3 is a moiety having the following structure: R3A is hydrogen; RS is hydrogen; Ar2 is: s is an integer of 1; each occurrence of RP1 is independently hydrogen, halogen, or -GRG1, wherein G is —SO2—, or —SO2NRG2—; and RG1 and RG2 are independently hydrogen, an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety; RB1, RB2 and RE are hydrogen; R4A and R4B are each Cl; L is C═O; and AR1 is 8. The compound of claim 7 wherein RP1 is selected from the group consisting of halogen and -GRG1, wherein G is —SO2— and RG1 is methyl. 9. The compound of claim 8 wherein AR1 is and RP1 is selected from the group consisting of F and SO2CH3. 10. A pharmaceutical composition comprising a compound of claim 7 and a pharmaceutically acceptable carrier or diluent, and optionally further comprising an additional therapeutic agent.